
Auris Medical Holding Ltd. Revenue 2011-2026 | EARS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Auris Medical Holding Ltd.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 174 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 174 K | 174 K | 174 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
75.1 M | $ 3.59 | -1.24 % | $ 1.07 B | ||
|
I-Mab
IMAB
|
88 M | - | - | $ 866 M | ||
|
ADMA Biologics
ADMA
|
510 M | $ 15.71 | -5.02 % | $ 3.74 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
912 K | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | ||
|
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
1 B | $ 20.29 | 2.17 % | $ 2.56 B | ||
|
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
614 M | $ 75.95 | -0.76 % | $ 1.47 B | ||
|
Applied Therapeutics
APLT
|
9.99 M | - | - | $ 8.42 M | ||
|
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.5 | -7.98 % | $ 383 M | ||
|
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - | ||
|
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
761 M | $ 34.35 | -3.74 % | $ 3.57 B | ||
|
AVEO Pharmaceuticals
AVEO
|
42.3 M | - | - | $ 521 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
882 K | $ 7.99 | -5.17 % | $ 34.6 M | ||
|
CorMedix
CRMD
|
65.4 K | $ 6.35 | -10.88 % | $ 323 M | ||
|
Champions Oncology
CSBR
|
56.9 M | $ 5.79 | -3.58 % | $ 79.1 M | ||
|
Axsome Therapeutics
AXSM
|
638 M | $ 160.64 | -2.1 % | $ 7.99 B | ||
|
BridgeBio Pharma
BBIO
|
502 M | $ 65.51 | -1.55 % | $ 12.5 B | ||
|
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | ||
|
Denali Therapeutics
DNLI
|
331 M | $ 19.73 | -3.17 % | $ 3.25 B | ||
|
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B | ||
|
Edesa Biotech
EDSA
|
329 K | $ 3.71 | -13.11 % | $ 11.9 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
1.5 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | ||
|
Equillium
EQ
|
36.1 M | $ 1.79 | 2.29 % | $ 62.2 M | ||
|
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | ||
|
BioLineRx Ltd.
BLRX
|
28.9 M | $ 2.75 | -1.96 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 60.6 | 0.28 % | $ 11.6 B | ||
|
Burford Capital Limited
BUR
|
330 M | $ 8.26 | -1.31 % | $ 1.36 B |